Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Merck KGaA sales and marketing update

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Supply/Service Merck launched its Centinel gene editing technology worldwide. The technology modifies CHO cell lines to generate lines resistant to minute virus of …

    Published on 9/19/2016
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer The U.K.s NICE issued draft guidance recommending against the use of Gazyvaro obinutuzumab from Roche in combination with Treanda bendamustine followed …

    Published on 9/19/2016
  • AbbVie, Bristol-Myers sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that …

    Published on 9/12/2016
  • Bayer sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer The U.K.s NICE issued final draft guidance recommending Xofigo radium-223 dichloride from Bayer to treat castration-resistant prostate cancer (CRPC), …

    Published on 9/12/2016
  • Express Scripts sales and marketing update

    Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Business: Inflammation Express Scripts introduced its Inflammatory Conditions Care Value Program, an optional program for Express Scripts clients aimed at …

    Published on 9/12/2016
  • Kyorin sales and marketing update

    Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Business: Inflammation, Generics Kyorin launched montelukast in Japan to treat bronchial asthma and allergic rhinitis. Montelukast is a generic of Kipres, which …

    Published on 9/12/2016
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Infectious The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Zepatier grazoprevir/elbasvir from Merck to treat HCV genotypes 1a, …

    Published on 9/12/2016
  • Valeant Pharmaceuticals sales and marketing update

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Business: Gastrointestinal Valeant launched an oral formulation of Relistor methylnaltrexone in the U.S. to treat opioid-induced constipation…

    Published on 9/12/2016
  • Bayer sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Ophthalmic The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Eylea aflibercept from Bayer to treat visual impairment in adults …

    Published on 9/5/2016
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The U.K.s NICE issued final guidance recommending the use of Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or …

    Published on 9/5/2016
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that added benefit was not proven for …

    Published on 9/5/2016
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Autoimmune Australias Pharmaceutical Benefits Advisory Committee (PBAC) recommended that Mercks biosimilar Brenzys etanercept could be marked as equivalent to …

    Published on 9/5/2016
  • Mylan sales and marketing update

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Inflammation Mylan said in several weeks it will launch a generic version of its EpiPen at a list price of $300 for a two-pack carton, which it said is a discount of …

    Published on 9/5/2016
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer The U.K.s NICE issued final guidance recommending the use of Bosulif bosutinib from Pfizer to treat chronic, accelerated and blast phase Philadelphia chromosome-…

    Published on 9/5/2016
  • Servier, Taiho sales and marketing update

    Servier, Neuilly-sur-Seine, France Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Business: Cancer The U.K.s NICE issued final guidance recommending Lonsurf trifluridine/tipiracil from Servier to treat metastatic …

    Published on 9/5/2016
  • Shire sales and marketing update

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Ophthalmic Shire launched Xiidra lifitegrast in the U.S. to treat signs and symptoms of dry eye disease in adults. The wholesale acquisition cost (WAC) of a 60…

    Published on 9/5/2016
  • UCB, Daiichi Sankyo sales and marketing update

    UCB Group (Euronext:UCB), Brussels, Belgium Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Neurology Daiichi and UCB launched Vimpat lacosamide in Japan as an adjunctive therapy for partial-onset seizures …

    Published on 9/5/2016
  • Bayer sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer The U.K.s NICE released draft guidance recommending against the use of Nexavar sorafenib from Bayer to treat advanced hepatocellular carcinoma in adults when …

    Published on 8/22/2016
  • CombiMatrix sales and marketing update

    CombiMatrix Corp. (NASDAQ:CBMX), Irvine, Calif. Business: Diagnostic CombiMatrix said Health Care Service Corp. (Chicago, Ill.) will include reimbursement for chromosomal microarray analysis for the evaluation of …

    Published on 8/22/2016
  • J&J, AbbVie sales and marketing update

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer The U.K.s NICE issued draft guidance recommending against the use of Imbruvica ibrutinib from Johnson & Johnson …

    Published on 8/22/2016
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cardiovascular Merck said it will discontinue marketing Zontivity vorapaxar in the U.S., effective Sept. 2. Merck said the decision was for business reasons and …

    Published on 8/22/2016
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer The U.K.s NICE issued draft guidance recommending against the use of Afinitor everolimus because it did not have plausible potential to be cost …

    Published on 8/22/2016
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Xalkori crizotinib from Pfizer for untreated, anaplastic lymphoma kinase (ALK)-…

    Published on 8/22/2016
  • Trovagene sales and marketing update

    Trovagene Inc. (NASDAQ:TROV), San Diego, Calif. Business: Diagnostic Trovagene said Blue Cross Blue Shield (BCBS) of Illinois will cover Trovagenes Trovera liquid biopsy tests. The biotech markets Trovera EGFR, a non-…

    Published on 8/22/2016
  • Amgen sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cancer The U.K.s NICE issued a final appraisal determination (FAD) recommending Imlygic talimogene laherparepvec from Amgen to treat unresectable melanoma that …

    Published on 8/15/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993